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cost—effectiveness of sequential adjuvant therapy vs. monother-
apies with aromatase inhibitors (AI) or tamoxifen in post-
menopausal women with Early-Stage breast cancer from the
Mexican health care payer’s perspective. METHODS: We used
a ten-year Markov analysis model to estimate costs and effec-
tiveness. Effectiveness measure was the % of patients free of
recurrence (local or distant). Transition probabilities were
obtained from international published literature. Comparators
were: tamoxifen 20 mg/day (ﬁve years); anastrozole 1 mg/day
(ﬁve years); letrozole 2.5 mg/day (ﬁve years) and the sequential
therapy with tamoxifen 20 mg/day (2.5-years) + exemestane 25
mg/day (ﬁve-years). Resource use estimations were performed
employing hospital records in an oncology hospital from the
Social Security Mexican Institute-IMSS in Mexico City (n = 104).
They included emergency, surgery, chemotherapy, outpatient and
inpatient services, drugs, oncology procedures, etc. Costs and
effectiveness measures were discounted 3% annually. One-way
and probabilistic sensitivity analyses were performed and accept-
ability curves were constructed. RESULTS: Sequential therapy
with tamoxifen followed by cross over to exemestane at 2.5-
years yielded 84.2% of patients free of recurrence in the ten-
years analysis followed of the two other AI monotherapies
(81.6%) and tamoxifen monotherapy (79.5%). The latter
showed the lower expected costs (US$23,968.3) followed by the
sequential therapy (US$29,077.3), anastrozole (US$30,615.2)
and letrozole (US$31,478.3). Sequential therapy was the option
most cost effective compared to AI monotherapies. Results were
robust to Monte Carlo second order sensitivity analysis. Accept-
ability curves showed the same results with a mean of 83.7% of
certainty. CONCLUSION: Sequential therapies should be con-
sidered as options more cost-effective compared to monothera-
pies. These results should be taken into account by Mexican
clinicians in the management of these patients.
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OBJECTIVES: To estimate cost-effectiveness of adjuvant
trastuzumab for one year following standard chemotherapy in
HER2-positive early breast cancer (EBC) versus standard therapy
alone (observation). METHODS: Markov model was developed
based on results of pivotal clinical study (HERA). The health
states included disease free survival, recurrence (local, contralat-
eral), distant metastases, cardiac adverse events and death. The
cohort simulation starts with 50-year-old patients who are con-
sidered disease free, i.e. have undergone surgery, chemo- and/or
radiotherapy. Effectiveness was measured in terms of QALY
gained. Population-based utilities were derived from published
literature. Yearly costs of each health state were established based
on the opinion of Polish experts from two oncology centers and
reported in PLN (1 EUR = 3.8 PLN in 2006). Direct medical costs
and outcomes were projected over patients’ lifetimes from a Polish
health care payer’s perspective, using 5% discount rate for both
or costs only. Probabilistic sensitivity analysis was performed.
RESULTS: The total lifetime costs/patient were estimated to be
198,294 PLN in trastuzumab and 62,812 PLN in no-trastuzumab
arm respectively. The main cost driver was the aquisition cost of
trastuzumab. The total QALYs generated with trastuzumab treat-
ment were 9.53 vs 7.5 for no trastuzumab treatment (discounted)
and 16.56 vs 11.9 QALY (without discounting) respectively. This
results in ICER for trastuzumab of 66,746 PLN/QALY (dis-
counted) and 30,769 PLN/QALY (with only costs discounted).
Probabilistic sensitivity analysis showed that for 50% simulations
the ICER remained below 60,000 PLN/QALY and for 97.5%—
below 88,624 PLN/QALY. CONCLUSION: The use of trast-
uzumab in EBC improves QALYs compared to observation alone.
Considering the suggested threshold for cost-effectiveness, 
calculated on the basis of one-year haemodialysis treatment costs
(60,000–74,700 PLN), adjuvant therapy with trastuzumab
appears to be cost-effective treatment for patients with HER2-
positive EBC in Poland.
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OBJECTIVES: Anastrozole primary adjuvant therapy compared
to tamoxifen signiﬁcantly improves disease free survival (DFS)
and time to recurrence (TTR) and signiﬁcantly reduces distant
metastases and contralateral breast cancers in PM women with
hormone-receptor positive early BC. METHODS: We developed
a Markov model describing the clinical history of PM women
with early BC that projected improvements in lifetime life years
gained (LYG), long-term costs, and cost-effectiveness of the
adjuvant treatment with anastrozole compared to that with
tamoxifen. The base case was a 64-year-old PM women with
hormone-receptor positive BC submitted to mastectomy and
without metastases. Transition probabilities came from the
ATAC study and other major studies from the medical literature.
The local management and costs of each health state was based
on a Delphi panel according to the private health care perspec-
tive. Outcomes were discounted at 3% annually. Sensitivity
analyses and a second order Monte Carlo simulation were per-
formed. RESULTS: The lifetime horizon analysis showed: Anas-
trozole in comparison to tamoxifen increased life expectancy
(LY) in 0,55 year; the incremental cost per LYG was
R$27.693,36; the tamoxifen group expenses in comparison to
the anastrozole group in recurrence states (loco-regional disease
and metastasis) and with adverse events were respectively 17%
and 16% higher. CONCLUSION: Improvements in DFS and
TTR with primary adjuvant anastrozole in postmenopausal
women with operable hormone-receptor positive breast cancer
improves patient outcomes in terms of LYG with an acceptable
cost-effectiveness ratio in Brazil.
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OBJECTIVES: While early studies showed the efﬁcacy of gran-
ulocyte colony-stimulating factor (G-CSF) in preventing febrile
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neutropenia (FN) in chemotherapy regimens with a high risk of
FN, pegﬁlgrastim was recently shown to decrease the relative risk
of FN by 0.94 in regimens with a moderate risk (<20%). We esti-
mated the cost-effectiveness ($ per FN episode avoided, $/life
year gained [LYG]) of pegﬁlgrastim primary (starting in cycle 1)
vs. secondary (after FN) prophylaxis in women with early-stage
breast cancer receiving chemotherapy with a moderate risk of
FN. METHODS: We created a decision-analytic model from a
payor’s perspective. The base case considers costs and outcomes
related to reduced FN. Secondary analyses considered potential
survival beneﬁts due to reduced FN-related mortality, and
cancer-speciﬁc long-term survival gains due to increased
chemotherapy dose intensity. Costs included drug costs, FN-
related hospitalizations and post-hospitalization costs. FN risk
and mortality, risk of chemotherapy relative dose intensity (RDI)
<85%, hazard ratio for mortality with RDI <85%, and risk
reduction with pegﬁlgrastim were based on a comprehensive lit-
erature review. Breast cancer mortality by stage and age-speciﬁc
mortality from other causes were obtained from Surveillance
Epidemiology and End Results and National Vital Statistics
Reports. Result robustness was tested using multi-way sensitiv-
ity analyses. RESULTS: For women with stage II breast cancer
receiving chemotherapy with FN risk of 17%, the incremental
cost-effectiveness ratio (ICER) was $41 K per FN episode
avoided. Adding survival beneﬁt due to avoiding FN mortality
yielded an ICER of $72 K/LYG. Adding all proven and hypoth-
esized beneﬁts yielded an ICER of $54 K/LYG. Factors that were
most inﬂuential for the base case ICER included (in order of
inﬂuence) study time horizon, FN case-fatality, baseline FN risk,
FN relative risk reduction, and cost of pegﬁlgrastim. CON-
CLUSION: The value of pegﬁlgrastim primary prophylaxis in
early-stage breast cancer is favorable compared with other oncol-
ogy therapies.
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OBJECTIVES: To assess the cost-effectiveness of breast cancer
risk assessment in primary care, with chemoprevention with
tamoxifen offered to high-risk women. METHODS: A Markov
model was developed to simulate the incidence, health conse-
quences, and costs of invasive breast cancer (IBC) and other clin-
ical events associated with a 5-year course of tamoxifen. Cohorts
at ages 50, 55, and 60 were stratiﬁed by 5-year cancer risk based
on the Gail model. Treatment criteria were deﬁned according to
alternative risk thresholds of 1.67% to 6%. Acceptance of (70%)
and compliance with (68%) chemoprevention were assumed to
be imperfect. Women receiving tamoxifen were assumed to be at
decreased risk for IBC and vertebral fracture, and increased risk
for endometrial cancer, stroke, and venous thromboembolic
events. Breast cancer incidence and survival were derived from
SEER. Other model parameters, including costs and utilities,
were estimated from published literature and clinical trial data.
We discounted costs (2006 US dollars) and quality-adjusted life
years (QALYs) at 3%/year. RESULTS: For 50-year-old women,
risk assessment and chemoprevention based on a 5-year cancer
risk of 4% or greater results in an incremental cost-effectiveness
ratio (ICER) of $49,900 compared to no risk assessment.
Expanding the criterion for chemoprevention to 3%, 2%, and
1.67% leads to incremental cost-effectiveness ratios of $54,400,
$106,000, and $163,000 per QALY, respectively. Thresholds
higher than 4% were weakly dominated. At age 60, ICERs
ranged from $35,300 to $1.3 million per QALY as the treatment
threshold was lowered from 6% to 1.67%. At age 65, thresh-
olds below 5% were dominated. CONCLUSION: Risk assess-
ment and chemoprevention is cost-effective at a $100 K/QALY
threshold at ages 50–65, but more selective criteria for chemo-
prevention at older ages is required to achieve any given cost-
effective criterion.
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OBJECTIVES: In HR positive ABC, HT may be considered stan-
dard treatment before institution of chemotherapy. However, HT
is sometimes substituted by CT early in the disease course, for
example after failure of ﬁrst-line HT. A common treatment
sequence in Brazil is anastrozole followed by successive lines of
docetaxel, capecitabine and gemcitabine. We evaluated the CE
of this treatment sequence (CT sequence) compared to several
other sequences (HT/CT sequences) in which anastrozole and
fulvestrant are used in ﬁrst and second lines, respectively, and
then followed by exemestane and megestrol or megestrol 
and capecitabine or exemestane and capecitabine or megestrol
and exemestane or exemestane and docetaxel, each pair intro-
duced as third and fourth lines, respectively. METHODS: A
Markov model describing the clinical history of HR positive,
ABC, projected improvements in terms of quality-adjusted life
months (QALM), costs, and CE of CT compared to HT/CT. The
time horizon is four treatment lines or the time to patient’s death,
whichever occurred ﬁrst. The simulations were with 10,000
patients for each treatment sequence studied. The reference
patient is a post-menopausal woman with HR positive ABC,
with previous deﬁnitive surgery and adjuvant HT with tamox-
ifen. The disease-progression probabilities for the different treat-
ment drugs/lines and, the quality of life for each health state were
based on the medical literature. Local management and costs of
each health state was based on a Delphi panel, according to the
private health care perspective. Outcomes were discounted at
3% annually. RESULTS: The CE of CT sequence in relation to
HT/CT sequences ranged from R$ 15,000 to R$ 552,000 per
QALM gained. CONCLUSION: As WHO-recommended cost-
utility threshold for Brazil is R$ 2435.75 per QALM gained, CT
is not cost effective in relation to treatment sequences contain-
ing successive lines of HT with fulvestrant in the second line and
introducing chemotherapy in later lines.
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OBJECTIVES: This study is an economic evaluation of currently
recommended colorectal cancer (CRC) screening procedures,
and strategies that incorporate chemopreventive options such as
aspirin or a cycooxygenase-2 inhibitor. METHODS: A decision
analysis model was constructed to compare alternative CRC
screening strategies. A Markov model was employed to simulate
the natural history of CRC. Markov states included Well, Well
with Polyp History, Well with CRC History, CRC-Local, CRC-
